Follow
Kiavash Hushmandi
Kiavash Hushmandi
Assistant Prof,Nephrology and Urology Department ,BUMS and UT
Verified email at ut.ac.ir
Title
Cited by
Cited by
Year
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
MDA Paskeh, M Entezari, S Mirzaei, A Zabolian, H Saleki, MJ Naghdi, ...
Journal of hematology & oncology 15 (1), 83, 2022
3232022
Association of the epithelial–mesenchymal transition (EMT) with cisplatin resistance
M Ashrafizadeh, A Zarrabi, K Hushmandi, M Kalantari, ...
International journal of molecular sciences 21 (11), 4002, 2020
2122020
Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis?
S Mirzaei, A Zarrabi, F Hashemi, A Zabolian, H Saleki, A Ranjbar, ...
Cancer Letters 509, 63-80, 2021
2002021
AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation
M Entezari, D Hashemi, A Taheriazam, A Zabolian, S Mohammadi, ...
Biomedicine & Pharmacotherapy 146, 112563, 2022
1902022
Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in …
AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, ...
The Lancet 403 (10440), 2133-2161, 2024
1672024
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease …
M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, ...
The Lancet 403 (10440), 2162-2203, 2024
1562024
Long non-coding RNAs in the doxorubicin resistance of cancer cells
S Ashrafizaveh, M Ashrafizadeh, A Zarrabi, K Husmandi, A Zabolian, ...
Cancer Letters 508, 104-114, 2021
1512021
New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities
M Ashrafizadeh, S Mirzaei, F Hashemi, A Zarrabi, A Zabolian, H Saleki, ...
Biomedicine & Pharmacotherapy 141, 111824, 2021
1492021
Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects
AJ Abadi, S Mirzaei, MK Mahabady, F Hashemi, A Zabolian, F Hashemi, ...
Phytotherapy Research 36 (1), 189-213, 2022
1442022
Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects
M Ashrafizadeh, A Zarrabi, F Hashemi, ER Moghadam, F Hashemi, ...
Life sciences 256, 117984, 2020
1362020
Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression
M Ashrafizadeh, S Mirzaei, MH Gholami, F Hashemi, A Zabolian, M Raei, ...
Carbohydrate polymers 272, 118491, 2021
1352021
The long and short non-coding RNAs modulating EZH2 signaling in cancer
S Mirzaei, MH Gholami, K Hushmandi, F Hashemi, A Zabolian, I Canadas, ...
Journal of hematology & oncology 15 (1), 18, 2022
1322022
Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance
S Mirzaei, AT Mohammadi, MH Gholami, F Hashemi, A Zarrabi, ...
Pharmacological research 167, 105575, 2021
1292021
Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
S Mirzaei, MH Gholami, F Hashemi, A Zabolian, MV Farahani, ...
Drug Discovery Today 27 (2), 436-455, 2022
1272022
Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy
M Ashrafizadeh, M Delfi, F Hashemi, A Zabolian, H Saleki, M Bagherian, ...
Carbohydrate Polymers 260, 117809, 2021
1272021
NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition
S Mirzaei, S Saghari, F Bassiri, R Raesi, A Zarrabi, K Hushmandi, G Sethi, ...
Journal of cellular physiology 237 (7), 2770-2795, 2022
1222022
Lung cancer cells and their sensitivity/resistance to cisplatin chemotherapy: Role of microRNAs and upstream mediators
M Ashrafizadeh, A Zarrabi, K Hushmandi, F Hashemi, ER Moghadam, ...
Cellular signalling 78, 109871, 2021
1132021
Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention
S Mirzaei, MDA Paskeh, E Okina, MH Gholami, K Hushmandi, M Hashemi, ...
Journal of Experimental & Clinical Cancer Research 41 (1), 214, 2022
1112022
Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response
M Ashrafizadeh, MDA Paskeh, S Mirzaei, MH Gholami, A Zarrabi, ...
Journal of Experimental & Clinical Cancer Research 41 (1), 105, 2022
1082022
Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches
M Ashrafizadeh, M Delfi, A Zarrabi, A Bigham, E Sharifi, N Rabiee, ...
Journal of controlled release 351, 50-80, 2022
1072022
The system can't perform the operation now. Try again later.
Articles 1–20